Invivyd Announces 180-Day Exploratory Clinical Efficacy Data From CANOPY Phase 3 Trial Of Pemivibart Showing 84% Relative Risk Reduction I Symptomatic COVID-19 Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Invivyd has announced promising 180-day exploratory clinical efficacy data from its CANOPY Phase 3 trial of Pemivibart, showing an 84% relative risk reduction in symptomatic COVID-19 compared to a placebo.
August 27, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's CANOPY Phase 3 trial of Pemivibart shows an 84% relative risk reduction in symptomatic COVID-19, indicating strong potential for the drug.
The significant reduction in symptomatic COVID-19 risk suggests that Pemivibart could be a successful treatment, likely boosting investor confidence and positively impacting IVVD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100